|
|
https://mb.cision.com/Public/18595/3810107/b359c1f1fb339964_800x800ar.png
UCB now at the inflection point =E2=80=93 ready to start a new phase of =
growth
=C2=B7 Revenue reached =E2=82=AC 2.6 billion 11%; 13% CER1, net sales w=
ere =E2=82=AC 2.4 billion 12%; 14% CER^1
=C2=B7 Underlying profitability adj. EBITDA^2 was =E2=82=AC 801 million =
2%; 9% CER^1, 31% of revenue
=C2=B7... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3806196/b33a6d913f634f09_800x800ar.png
UCB Announces EU Regulatory Filing for Bimekizumab for the Treatment of =
Moderate to Severe Hidradenitis Suppurativa
=C2=B7 Regulatory filing supported by data from two bimekizumab Phase 3 stu=
dies in hidradenitis suppurativa
=C2=B7 Hidradenitis suppurativa is a chronic, painful, inflammatory skin co=
ndition... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3798140/94957ae8ccb7ec6a_800x800ar.png
UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio at=
9th Congress of the European Academy of Neurology EAN Meeting
=C2=B7 Results presented across UCB=E2=80=99s generalized myasthenia gravis=
gMG portfolio
=C2=B7 Expanded data from the MycarinG and RAISE studies showcase further... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3794654/bf745fb9dd52cf2b_800x800ar.png
UCB announces U.S. FDA approval of RYSTIGGO^=C2=AE rozanolixizumabnoli=
for the treatment of adults with generalized myasthenia gravis
=C2=B7 FDA approval of RYSTIGGO^=C2=AE rozanolixizumabnoli has been gran=
ted under the Priority Review designation for the treatment of generalized =
myasthenia gravis gMG in... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3794280/96cf8050614df072_800x800ar.png
UCB Provides Update on U.S. FDA Review of the Biologics License Applicat=
ion for Bimekizumab
Brussels Belgium, 26th June 2023 =E2=80=93 18:30 CEST =E2=80=93 Regulated=
Information =E2=80=93 Inside Information =E2=80=93 UCB, a global biopharma=
ceutical company, today announced that the Biologics License... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3794110/a43a31146c3d9d83_800x800ar.png
Change in UCB=E2=80=99s Executive Committee
=C2=B7 UCB EVP, Head of Neurology Solutions Charl van Zyl will leave the co=
mpany to become CEO of Lundbeck
Brussels Belgium June 26, 2023 =E2=80=93 =C2=A02 PM CEST =E2=80=93 UCB =
announces today that its Head of Neurology Solutions Charl van Zyl has deci=
ded to... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3789790/b877eda2d0ae2bc7_800x800ar.png
UCB showcases commitment to transforming outcomes for people living with=
epilepsy and rare epileptic syndromes at European Pediatric Neurology Soci=
ety EPNS Annual Congress
=C2=B7 Data presented from UCB=E2=80=99s wide ranging portfolio include the=
safety profile, efficacy, and tolerability of... Lire le communiqué |
|
| |
|
| |
